- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05496517
Ovarian Cancer Individualized Scoring System Scoring System (OCISS)
Ovarian Cancer Individualized Scoring System (OCISS) for Prediction of Ovarian Cancer Prognosis
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Ovarian cancer (OC) is one of the most common types of malignant tumors and the eighth cause of cancer-related mortality in women.[1] Among gynecological cancers, it is ranked the third following cervical and uterine cancers and is associated with the worst prognosis
[1]. Globally, there are 313,959 new cases and 207,252 deaths of OC annually [1].
Compared to breast cancer, OC is approximately three times more lethal [2]. The high mortality rate of OC is attributed to the capacious anatomical space through which the tumor can grow before it causes significant symptoms, growth of the tumor within abdominal cavity rendering spread of malignant cells widespread and prompt, direct lymphatic drainage to aortic lymph nodes, lack of specific diagnostic symptoms, and unavailability of an efficient screening strategy [3,4]. Symptoms of OC are nonspecific and include vague abdominal pain, abdominal bloating, urinary frequency, early satiety, feeling full, or changes in bowel habits, most of which mimic common gastrointestinal symptoms [5]. Risk factors of OC include obesity, old age, smoking, genetic predisposition, and endometriosis [6,7]. FIGO staging is considered the standard classification system that determines prognosis and management of newly diagnosed OC. However, there are numerous gaps in this staging system that would limit interpretation of clinically relevant data [8]. For instance, the staging system does not consider crucial disease prognostic factors, such as histological type and grade, which are usually considered separately based on available evidence and internal policies. This multi-layer guidance adds to the complexity of decision making. Similarly, personalized management is overlooked since these staging systems do not appreciate individual characteristics such as age, menopausal states, comorbidities, and genetic predisposition. All patients with positive lymph nodes are grouped into a single stage in FIGO staging system, which creates a very diverse group of patients with highly variable survival rates [9]. Management of ovarian cancer is surgical and comprises bilateral sapling-oophorectomy, total abdominal hysterectomy , and infracolic omentectomy. Additional surgical steps and neoadjuvant therapy are potentially determined by disease characteristics. Extent of surgery and neoadjuvant treatment is directly related to postoperative comorbidities and contributes to long term prognosis.
[10]. Therefore, development of an individualized prognostic and decision-making system, based on large multicenter studies, would facilitate accurate prediction of disease prognosis and determination of individualized management strategy.
The study will comprise at least 8 international cancer centers. Data of patients, newly diagnosed with OC between January 2010 and December 2016, will be retrospectively collected. Therefore, a follow-up of at least 5 years would be granted. All women who will be diagnosed with primary ovarian cancer at any stage, of all histological types and grades eligible for the study. All contributing centers should acquire institutional review board (IRB) approval prior to data collection.
Inclusion criteria:
- Women diagnosed with ovarian cancer between January 2010 and December 2016.
- Primary non-recurrent diagnosis of ovarian cancer.
- Women should be diagnosed and managed by the corresponding center.
- Patients with adequate clinical and pathological data
Exclusion criteria:
- Inadequate information and follow-up for at least 5 years.
- Authorization to use anonymous patient data for research purposes. Data will be collected using an excel spreadsheet designed for this study and shared among contributing centers. Data include patients' demographics such as age, parity, body mass index, ethnicity, smoking index, contraception method, menopausal status, medical comorbidities [coronary artery disease, diabetes on insulin, hypertension, chronic renal 3 disease, chronic lung disease, thyroid dysfunction], preoperative imaging [cancer stage, involvement of ovaries, surface involvement, uterine involvement, tubal involvement, inguinal lymph nodes (number, largest diameter), extra abdominal lymph nodes (size and enlargement), abdominal invasion (omental deposits > 2cm, peritoneal carcinomatosis), other pelvic invasion], positive cytology, grade (high/low), pleural effusion and cytology, ascites, performance status, histological type, biomarkers, BRCA I and II (germline or somatic), and serum albumin level. Details of management plan will be collected including treatment approach [Time from diagnosis to surgery, Surgical approach, PA lymphadenectomy (systematic, selective, none)], chemotherapy [systematic or intraperitoneal], and other treatments given.
Treatment outcomes such as complications, debulking success, spill, nodal metastasis, microscopic peritoneal metastasis, microscopic omental metastasis, response to chemotherapy, and CA 125 changes will be included. Data will not include any identifiable information.
Type d'étude
Inscription (Anticipé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Sherif Shazly
- Numéro de téléphone: +4407554480388
- E-mail: sherif.shazly.mogge@gmail.com
Lieux d'étude
-
-
-
Alexandria, Egypte, 21516
- Alexandria University Main Hospital
-
Contact:
- Ahmed H. Ismail
- Numéro de téléphone: 01144557597
- E-mail: ahmed.ismail.mogge@gmail.com
-
Assiut, Egypte, 71511
- Assiut Hospitals university
-
Contact:
- Manar M. Ahmed
- Numéro de téléphone: 01128793950
- E-mail: manar.mahran.mogge@gmail.com
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
Women diagnosed with ovarian cancer between January 2010 and December 2016.
- Primary non-recurrent diagnosis of ovarian cancer.
- Women should be diagnosed and managed by the corresponding center.
- Patients with adequate clinical and pathological data
Exclusion Criteria:
• Inadequate information and follow-up for at least 5 years.
- Authorization to use anonymous patient data for research purposes.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cohorte
- Perspectives temporelles: Rétrospective
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Cancer-specific survival (CSS) rate at 5 years
Délai: Within 5 years after diagnosis of ovarian cancer
|
Percentage of women newly diagnosed with ovarian cancer who do not die from ovarian cancer after 5 years
|
Within 5 years after diagnosis of ovarian cancer
|
Cancer-specific survival (CSS) rate at 3 years
Délai: Within 3 years after diagnosis of ovarian cancer
|
Percentage of women newly diagnosed with ovarian cancer who do not die from ovarian cancer after 3 years
|
Within 3 years after diagnosis of ovarian cancer
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Recurrence-free survival (RFS) rate at 5 years
Délai: Within 5 years of diagnosis of ovarian cancer
|
Percentage of newly diagnosed women who do not experience disease recurrence during follow-up
|
Within 5 years of diagnosis of ovarian cancer
|
Recurrence-free survival (RFS) rate at 3 years
Délai: Within 3 years of diagnosis of ovarian cancer
|
Percentage of newly diagnosed women who do not experience disease recurrence during follow-up
|
Within 3 years of diagnosis of ovarian cancer
|
Collaborateurs et enquêteurs
Parrainer
Publications et liens utiles
Publications générales
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
- Caan BJ, Thomson CA. Breast and ovarian cancer. Optim Women's Heal through Nutr. Published online 2007:229-263. doi:10.1369/0022155411428469
- Urban N. Early detection of ovarian cancer: Methodological considerations. Int J Gynecol Obstet. 2000;70:D9-D9. doi:10.1016/s0020-7292(00)82512-6
- Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004 Apr;3(4):355-66. Epub 2004 Feb 5. Review.
- Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. JAMA. 2004 Jun 9;291(22):2705-12. doi: 10.1001/jama.291.22.2705.
- Jordan SJ, Green AC, Whiteman DC, Webb PM; Australian Ovarian Cancer Study Group. Risk factors for benign, borderline and invasive mucinous ovarian tumors: epidemiological evidence of a neoplastic continuum? Gynecol Oncol. 2007 Nov;107(2):223-30. Epub 2007 Jul 27.
- Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H. Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019 Apr 30;11:287-299. doi: 10.2147/IJWH.S197604. eCollection 2019.
- Salvo G, Odetto D, Pareja R, Frumovitz M, Ramirez PT. Revised 2018 International Federation of Gynecology and Obstetrics (FIGO) cervical cancer staging: A review of gaps and questions that remain. Int J Gynecol Cancer. 2020 Jun;30(6):873-878. doi: 10.1136/ijgc-2020-001257. Epub 2020 Apr 1. Review.
- Wright JD, Matsuo K, Huang Y, Tergas AI, Hou JY, Khoury-Collado F, St Clair CM, Ananth CV, Neugut AI, Hershman DL. Prognostic Performance of the 2018 International Federation of Gynecology and Obstetrics Cervical Cancer Staging Guidelines. Obstet Gynecol. 2019 Jul;134(1):49-57. doi: 10.1097/AOG.0000000000003311.
- McCorkle R, Pasacreta J, Tang ST. The silent killer: psychological issues in ovarian cancer. Holist Nurs Pract. 2003 Nov-Dec;17(6):300-8. Review.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Anticipé)
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Tumeurs par type histologique
- Tumeurs
- Tumeurs urogénitales
- Tumeurs par site
- Carcinome
- Tumeurs, glandulaires et épithéliales
- Tumeurs génitales, femme
- Maladies du système endocrinien
- Maladies ovariennes
- Maladies annexielles
- Troubles gonadiques
- Tumeurs des glandes endocrines
- Tumeurs ovariennes
- Carcinome épithélial ovarien
Autres numéros d'identification d'étude
- MOGGE-GO03
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Cancer des ovaires
-
AstraZenecaRecrutementAdv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian CancerEspagne, États-Unis, Belgique, Royaume-Uni, France, Hongrie, Canada, Corée, République de, Australie